FDA Updates Expanded Access Program to Boost Patient Participation and Access

The FDA made updates to its expanded access (EA) program to improve upon patient experiences in the overall program as well as remove administrative obstacles.  The FDA expanded access program was set up for patients with serious health issues who could not for whatever reason access a drug through a clinical trial. Through an application process patients can access experimental drugs that are yet to be approved for the market but have been proven safe in clinical research.  Read the FDA notice as well as quotes from FDA Commissioner Scott Gottlieb.